Traders should monitor the shareholder vote on July 8 and regulatory HSR/German clearance. The $3.16 cash price sets an effective floor near that level. CVR upside to $100M aggregate is real but contingent on achieving aggressive 2027 bempedoic acid sales ($300M+) or enbumyst sales ($160M+). If the deal closes, delisting will occur shortly after.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK AT ENTRY AT T+20- T+0 · Jun 8 $3.15entry
- T+1 · 5mo ago −0.32%α −0.02% · $3.14
- T+5 · 5mo ago 0.00%α −2.11% · $3.15
- T+20 · 4mo ago 0.00%α −1.63% · $3.15
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plus one CVR per share. The board unanimously recommends a FOR vote. The deal requires majority approval of outstanding shares, with the special meeting on July 8, 2026. Total transaction costs are ~$1.08 billion, funded by $706.1M equity commitments and up to $550M debt. CVRs offer up to $100M in total contingent payments tied to sales milestones.
Key Financial Metrics
Key Facts
- Merger consideration: $3.16/share cash + 1 CVR per share
- Total funding ~$1.08B: $706.1M equity from ArchiMed funds + up to $550M debt commitment from BPCR/ BioPharma Credit
- Special meeting July 8, 2026; required vote is majority of outstanding shares (257.7M shares outstanding)
- CVRs: up to $40M aggregate if U.S. bempedoic acid net sales exceed $300M in CY 2027 (max $350M); up to $60M if enbumyst U.S. net sales exceed $160M in any single CY through 2030
- Board and financial advisor Centerview Partners opined that consideration is fair from a financial point of view
- Company termination fee: $34.2M; Parent termination fee: $68.3M
- Expected close: Q3 2026; HSR and German merger control filings submitted May 15, 2026
- No dissenting directors; board recommendation was unanimous
Financial Impact
Total transaction size ~$1.08 billion in cash for equity and debt paydown/fees; $3.16/share cash consideration implies ~$814M equity value on 257.7M shares outstanding; up to $100M additional CVR payments contingent on sales milestones
Risk Factors
- Shareholder vote failure: requires majority of all outstanding shares, not just votes cast, abstentions/failures to vote count as AGAINST
- Regulatory delay or antitrust conditions from HSR or German Federal Cartel Office
- CVR payments uncertain and could be zero if sales milestones not met
- Debt financing terms or conditions may delay close if tranche A funding conditions not satisfied
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-071107 |
| Document: tm2615754-2_defm14a.htm | 0001104659-26-071107 |
Track record
21 reports on ESPR
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers